Bristol-Myers Squibb To Sell Australian Manufacturing Facility To Generics Maker Sigma
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Bristol-Myers Squibb revealed Sept. 7 that it plans to sell its Australian manufacturing facility in Melbourne to generic drug maker Sigma Pharmaceuticals for roughly AU$60 million. The Melbourne-based plant is the only production facility held by BMS in Australia
You may also be interested in...
BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation
Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary
BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation
Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary
BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation
Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary